Patent ID: 11939389
Assignee: NOVARTIS AG
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A | IPC A  C

Claim 12:
13. The method of claim 12, wherein:
(a) the PD-1 inhibitor is selected from the group consisting of PDR001, nivolumab, pembrolizumab, MEDI0680, REGN2810, TSR-042, PF-06801591, and AMP-224;
(b) the PD-L1 inhibitor is selected from the group consisting of FAZ053, atezolizumab, avelumab, durvalumab, and BMS-936559;
(c) the LAG-3 inhibitor is selected from the group consisting of LAG525, BMS-986016, TSR-033, MK-4280 and REGN3767;
(d) the TIM-3 inhibitor is selected from the group consisting of MBG453, TSR-022, and LY3321367;
(e) the CTLA-4 inhibitor is ipilimumab or tremelimumab;
(f) the combination of both an IL-15 polypeptide and an IL-15Ra polypeptide is hetIL-15; or
(g) the mTOR inhibitor is RAD001 or rapamycin.